Microrna-185 inhibits proliferation by targeting c-Met in human breast cancer cells

Experimental and Therapeutic Medicine

Volumn 8, Issue 6, 2014, Pages 1879-1883

  Fu, Peifen ^a   Du, Feiya ^a   Yao, Minya ^a   Lv, Kezhen ^a   Liu, Yu ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Breast cancer; Cell proliferation; c Met; miR 185

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 185; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MTT ASSAY; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE POLYMERASE CHAIN REACTION; RNA EXTRACTION; SPECTROPHOTOMETER; UPREGULATION; WESTERN BLOTTING;

EID: 84908207918     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1999     Document Type: Article

References (24)

1. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
2. Serrano MJ, Rovira PS, Martinez-Zubiaurre I, et al: Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med 4: 43-48, 2012.
3. Yamaguchi M, Kwong YL, Kim WS, et al: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29: 4410-4416, 2011.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTG); Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379: 432-444, 2012.
5. Fang YX and Gao WQ: Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 33: 135-147, 2014.
6. Nazarov PV, Reinsbach SE, Muller A, et al: Interplay of microRNAs, transcription factors and target genes: linking dynamic expression changes to function. Nucleic Acids Res 41: 2817-2831, 2013.
7. van Kouwenhove M, Kedde M and Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11: 644-656, 2011.
8. Marcucci G, Maharry KS, Metzeler KH, et al: Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 31: 2086-2093, 2013.
9. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
10. Voorhoeve PM: MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochim Biophys Acta 1805: 72-86, 2010.
11. Xiang Y, Ma N, Wang D, et al: MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 33: 378-386, 2014.
12. Östling P, Leivonen SK, Aakula A, et al: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 71: 1956-1967, 2011.
13. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
14. Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949, 2005.
15. Zhou M, Liu Z, Zhao Y, et al: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496-21507, 2010.
16. Zhang CM, Zhao J and Deng HY: MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci 20: 79, 2013.
17. Lal A, Navarro F, Maher CA, et al: miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to ʻseedlessʼ 3'UTR microRNA recognition elements. Mol Cell 35: 610-625, 2009.
18. Powell-Coffman JA and Coffman CR: Apoptosis: Lack of oxygen aids cell survival. Nature 465: 554-555, 2010.
19. Higgs G and Slack F: The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma 3: 17, 2013.
20. Liu M, Lang N, Chen X, et al: miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. Cancer Lett 301: 151-160, 2011.
21. Maroun CR and Rowlands T: The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther 142: 316-338, 2014.
22. Li C, Wu JJ, Hynes M, et al: c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141: 2218-2227, 2011.
23. Zhang W, Mendoza MC, Pei X, et al: Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem 287: 11850-11858, 2012.
24. Tang MK, Zhou HY, Yam JW and Wong AS: c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 12: 128-138, 2010.